who this notebook is
About CJC-1295 Safe
A friendly, independent reading of the published research — and a clear account of what this site is and what it is not.
What this site is
CJC-1295 Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The aim is simple: take a compound that forums hype and conflate, and walk a curious reader through it gently and honestly. That means leading with what the studies actually measured — the GH and IGF-1 kinetics, the DAC-versus-no-DAC half-life difference, the once-daily mouse-growth result — and being equally plain about the honest gaps: no long-term human safety data, no approval anywhere, a discontinued Phase 2 program, and a real IGF-1/cancer-risk question in the epidemiology [7].
What "safe" means in our name
The word "safe" in this site's name is editorial framing, not a claim. It describes the posture we take toward the literature — careful, due-diligence-first, skeptical of confident protocols that no trial supports — not a verdict that the compound is safe. CJC-1295 is an unapproved research chemical, and we say so on every relevant page.
We lead the cautionary material first, in plainly marked notes, precisely because a friendly surface should never soften an honest message. The cheerful field-notebook style is here to make a thin, technical literature readable, not to sell it.
How we work
Every quantitative claim on the site — a dose, a half-life, a percentage change in growth hormone — maps to a numbered citation in the full reference list, drawn from PubMed-indexed journals. Where the chemical registries disagree (they disagree on CJC-1295's exact molecular formula), we say so rather than paper over it. Where the human evidence stops, we stop with it.
We link only within this site. We do not recommend doses, sources, or vendors. If you want the science, it is all here, sorted into a research page, a GH / IGF-1 axis research page, a DAC vs no-DAC (Modified GRF 1-29) page, and a plain-spoken FAQ.
A note on the daisies
The cheerful style is deliberate, and so is its limit. A thin, technical literature about an unapproved compound is easy to make either intimidating or hyped; we have tried to make it simply readable — a friendly notebook a curious person can follow without a pharmacology degree. The illustrations and the soft palette are there to lower the barrier to reading, never to lower the seriousness of the message.
So the cautionary material always comes first and is always marked plainly: no long-term human safety data, no approval, a discontinued program, a real IGF-1/cancer-risk question, and prohibition in sport. If those notes read as gentle, it is the tone that is gentle, not the verdict. A reader who leaves knowing exactly what the studies measured — and exactly where they stop — is the whole point.